Mauna Kea Technologies (Paris, France) has received FDA clearance for use of its Cellvizio confocal laser endomicroscopy platform in surgery. The Celioflex probe can be delivered endoscopically or laparoscopically through a trocar and manipulated in the surgical field using standard laparoscopic instruments.
By providing precise real-time visualization of tissue during surgery, the tool aims to help surgeons confirm the absence or presence of metastasis that may not be visible preoperatively. Cellvizio could also help surgeons identify tumor margins, evaluate responses to treatment, and improve surgical planning. In addition, it could help pathologists better target malignant lesions for improved frozen section sampling.
In October 2015, the company announced a marketing strategy based on development of new partnerships positioned to incorporate Cellvizio into established platforms.
